Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Technical Update on Equity Market - Research on MFS Multimarket Income Trust, Vanda Pharmaceuticals, Western Asset Emerging Markets Debt Fund and Angie's List

Accesswire November 12, 2015

Developments in the Equity Market - Research on Cara Therapeutics, Vanda Pharmaceuticals, Carriage Services and Internap

Accesswire November 10, 2015

Vanda Pharmaceuticals to Participate in the Citi 2015 Global Healthcare 1x1 Conference

PR Newswire November 4, 2015

Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results

PR Newswire November 3, 2015

A Look on Scrips from Materials and Healthcare Sectors - Research on Vanda Pharmaceuticals, Westlake Chemical Partners, Global Brass and Copper Holdings, and Tredegar

Accesswire November 3, 2015

Vanda Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 3, 2015

PR Newswire October 15, 2015

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

PR Newswire October 14, 2015

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

PR Newswire September 23, 2015

Vanda Announces FDA Has Accepted for Review the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

PR Newswire September 15, 2015

Vanda Pharmaceuticals Announces the Appointment of General Counsel

PR Newswire September 14, 2015

Vanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation

PR Newswire September 10, 2015

Vanda Pharmaceuticals Announces the Appointment of European General Manager

PR Newswire September 8, 2015

Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

PR Newswire August 10, 2015

HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet

PR Newswire August 5, 2015

Vanda Announces Listing of Four New Fanapt® Patents in the FDA Orange Book

PR Newswire August 3, 2015

Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results

PR Newswire July 29, 2015

Vanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015

PR Newswire July 9, 2015

HETLIOZ® Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind

PR Newswire July 7, 2015

Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book

PR Newswire July 2, 2015

Vanda Announces Positive Results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) Demonstrating the Long-Term Maintenance Effects of Fanapt® (iloperidone)

PR Newswire June 23, 2015